Spero Therapeutics (NASDAQ:SPRO) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research note issued to investors on Monday, AnalystRatings.com reports. They currently have a $27.00 target price on the stock.

“916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34.”,” HC Wainwright’s analyst commented.

SPRO has been the subject of several other research reports. Cantor Fitzgerald reissued a buy rating and issued a $27.00 target price on shares of Spero Therapeutics in a research note on Thursday, May 9th. Zacks Investment Research downgraded shares of Spero Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 17th. ValuEngine raised shares of Spero Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, TheStreet downgraded shares of Spero Therapeutics from a c- rating to a d+ rating in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Spero Therapeutics has a consensus rating of Buy and a consensus price target of $20.60.

Shares of SPRO stock opened at $9.57 on Monday. The firm has a 50-day moving average price of $10.40 and a 200 day moving average price of $11.55. Spero Therapeutics has a twelve month low of $5.52 and a twelve month high of $14.48. The company has a market capitalization of $178.02 million, a price-to-earnings ratio of -3.68 and a beta of 2.08. The company has a current ratio of 17.48, a quick ratio of 17.48 and a debt-to-equity ratio of 0.04.

Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.22%. The firm had revenue of $2.16 million during the quarter, compared to analyst estimates of $6.95 million. As a group, research analysts predict that Spero Therapeutics will post -3.02 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Marshall Wace LLP increased its holdings in shares of Spero Therapeutics by 475.8% during the second quarter. Marshall Wace LLP now owns 17,699 shares of the company’s stock valued at $204,000 after purchasing an additional 14,625 shares during the period. Novo Holdings A S acquired a new position in shares of Spero Therapeutics during the second quarter valued at $5,363,000. Vanguard Group Inc. increased its holdings in shares of Spero Therapeutics by 4.5% during the second quarter. Vanguard Group Inc. now owns 437,204 shares of the company’s stock valued at $5,032,000 after purchasing an additional 18,814 shares during the period. BlackRock Inc. increased its holdings in shares of Spero Therapeutics by 56.0% during the second quarter. BlackRock Inc. now owns 656,778 shares of the company’s stock valued at $7,559,000 after purchasing an additional 235,691 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in shares of Spero Therapeutics during the second quarter valued at $115,000. 46.75% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Article: The limitations of an equal weight rating

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.